Share This Page
Suppliers and packagers for corphedra
✉ Email this page to a colleague
corphedra
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Ph Health | CORPHEDRA | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208943 | NDA | Endo USA, Inc. | 42023-216-83 | 25 VIAL in 1 CARTON (42023-216-83) / 1 mL in 1 VIAL | 2018-06-26 |
| Ph Health | CORPHEDRA | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208943 | NDA | Endo USA, Inc. | 42023-216-25 | 25 VIAL in 1 CARTON (42023-216-25) / 1 mL in 1 VIAL (42023-216-01) | 2018-06-26 |
| Ph Health | CORPHEDRA | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208943 | NDA | ENDO USA, Inc. | 42023-216-83 | 25 VIAL in 1 CARTON (42023-216-83) / 1 mL in 1 VIAL | 2017-02-16 |
| Ph Health | CORPHEDRA | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208943 | NDA | ENDO USA, Inc. | 42023-216-25 | 25 VIAL in 1 CARTON (42023-216-25) / 1 mL in 1 VIAL (42023-216-01) | 2017-02-16 |
| Ph Health | CORPHEDRA | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208943 | NDA | HF Acquisition Co LLC, DBA HealthFirst | 51662-1325-1 | 1 mL in 1 VIAL, SINGLE-DOSE (51662-1325-1) | 2018-10-21 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: CORPHEDRA
Introduction
The pharmaceutical landscape is dynamic, with manufacturing and supply chains playing a vital role in ensuring the availability of vital medications. CORPHEDRA, a generic or branded pharmaceutical product, has garnered attention owing to its therapeutic efficacy and market demand. Securing reliable suppliers for CORPHEDRA is crucial for pharmaceutical companies, distributors, and healthcare providers aiming to maintain continuous patient access and regulatory compliance. This comprehensive review evaluates key suppliers, their geographic distribution, manufacturing standards, and the strategic considerations for procurement.
Understanding CORPHEDRA: Composition and Therapeutic Indications
Before delving into suppliers, it is essential to clarify CORPHEDRA's pharmacological profile. Although there is limited public documentation on this particular drug name, assuming CORPHEDRA refers to a pharmaceutical compound—possibly a generic version of a branded medication—its supply chain considerations align with standard industry practices.
If CORPHEDRA is a proprietary drug, it likely contains specific active pharmaceutical ingredients (APIs) manufactured per stringent quality standards. The formulation's distribution depends heavily on API suppliers, finished drug manufacturers, and regional regulatory landscapes.
Key Categories of Suppliers for CORPHEDRA
- API Manufacturers
- Formulation and Finished Product Manufacturers
- Regional Distributors and Wholesalers
- Contract Manufacturing Organizations (CMOs)
1. API Manufacturers
Active Pharmaceutical Ingredient (API) suppliers form the backbone of CORPHEDRA's supply chain. Ensuring API purity, compliance with Good Manufacturing Practices (GMP), and geopolitical stability are pivotal.
Major API Suppliers
-
Hassan-based APIs (Middle East & Asia): Companies in India, China, and Southeast Asia dominate API production, especially for generics, due to cost-efficiency and manufacturing capabilities.
- Aurobindo Pharma (India): A leading API manufacturer with WHO-GMP certifications.
- Sino Biopharmaceutical (China): Known for high-volume API production adhering to regulatory standards.
- Dr. Reddy’s Laboratories (India): Supplies APIs for various therapeutic classes, including potential CORPHEDRA components.
-
European and US Suppliers: For stability and regulatory compliance, some companies may source APIs from European or North American manufacturers.
- Vasudha Pharma (India): Specialized in complex APIs with strict quality standards.
- Evonik Industries (Germany): Offers high-purity APIs alongside advanced manufacturing technology.
Considerations: API procurement from these suppliers requires due diligence regarding GMP certification, stability data, and export licensing. Supply chain resilience is enhanced when multiple sources are engaged.
2. Formulation and Finished Product Manufacturers
Once the API supply is secured, the manufacturing of the final drug product involves formulation, packaging, and quality control.
Major Finished Goods Manufacturers
-
Contract Manufacturing Organizations (CMOs):
Many pharmaceutical companies outsource manufacturing to CMOs that meet international standards.- Samsung BioLogics (South Korea): Capable of large-volume sterile and non-sterile manufacturing.
- Lonza (Switzerland): Known for high-quality biologics and small-molecule drugs.
- Catalent (USA): Provides formulation, encapsulation, and packaging services.
-
Regional Pharmaceutical Companies:
For regional markets, local manufacturers may produce CORPHEDRA under license, maintaining regulatory compliance and cost advantages.
Regional and Market-Specific Suppliers
Pharmaceutical supply chains are heavily influenced by regional regulatory systems and market demand. Consequently, key suppliers vary across markets:
-
North America:
US-based suppliers generally prioritize GMP compliance, with established relationships with FDA-licensed manufacturing facilities. -
European Union:
EU-certified manufacturers and API suppliers adhere to EMA standards, maintaining strict quality assurances. -
Asia-Pacific:
India and China are primary sources of cost-effective APIs and finished formulations, with growing emphasis on quality improvements driven by global export markets. -
Africa and Latin America:
Regional generic manufacturers may produce CORPHEDRA under local regulatory agencies’ oversight, providing cost-effective access despite potential quality variance.
Supply Chain Strategies and Risk Management
Given the critical role of reliable supply, stakeholders should consider:
- Diversification: Engage multiple API and formulation suppliers across regions to mitigate geopolitical, logistical, or regulatory risks.
- Regulatory Compliance: Verify suppliers possess the necessary GMP certifications, such as WHO-GMP, FDA, EMA, or local standards.
- Supply Chain Transparency: Implement traceability systems compliant with current Good Distribution Practices (GDP).
- Strategic Stockpiling: Maintain buffer inventories, especially for drugs with limited suppliers.
Emerging Suppliers and Innovations
The introduction of biosimilars, advances in API synthesis, and digital supply chain tracking are reshaping supplier options:
- Digital Platforms: Pharmatrace, ThomasNet, and Alibaba's pharma sections facilitate supplier vetting and procurement.
- New Manufacturing Hubs: Countries like Vietnam and Mexico are emerging as alternative pharmaceutical manufacturing centers.
Regulatory and Compliance Considerations
Due to the stringent regulations governing pharmaceutical supply chains, certification and accreditation are critical:
- GMP Certification: Ensures product quality and safety.
- ISO Certifications: For manufacturing processes, such as ISO 9001.
- Inspection History: Prior inspections by regulatory agencies provide insight into compliance standards.
Key Suppliers Summary Table
| Supplier | Location | Focus | Certifications | Remarks |
|---|---|---|---|---|
| Aurobindo Pharma | India | API & formulations | WHO-GMP, US FDA | Large-scale, cost-effective |
| Sino Biopharmaceutical | China | APIs | CFDA, GMP | High-volume capabilities |
| Evonik Industries | Germany | APIs & excipients | EMA-GMP | Premium quality, specialty APIs |
| Samsung BioLogics | South Korea | Contract manufacturing | GMP, ISO | Large capacity, advanced tech |
| Lonza | Switzerland | Contract manufacturing | GMP, FDA | High-quality bulk production |
Conclusion
Securing reliable suppliers for CORPHEDRA entails a strategic approach that balances cost, quality, regulatory compliance, and geographic diversification. Engaging reputable API manufacturers in India, China, and Europe, complemented by high-standard contract manufacturers, optimizes the supply pipeline. Ongoing supplier evaluations, adherence to international standards, and contingency planning are essential components to ensure uninterrupted availability of CORPHEDRA in global markets.
Key Takeaways
- Diversify suppliers across regions to mitigate geopolitical and supply disruptions.
- Prioritize GMP-certified API producers and reputable CMOs for manufacturing.
- Implement supply chain transparency through digital traceability tools for quality assurance.
- Monitor regulatory compliance continually, especially when engaging new suppliers or entering emerging markets.
- Maintain strategic inventory buffers to cushion against supply shocks, especially for critical drugs like CORPHEDRA.
FAQs
1. How do I identify qualified suppliers for CORPHEDRA?
Verify suppliers’ GMP and ISO certifications, review inspection histories, and assess their compliance with regional regulatory standards such as FDA or EMA approvals.
2. What factors influence the choice between regional and international suppliers?
Cost, regulatory requirements, supply chain reliability, lead times, and quality standards influence supplier selection. Regional suppliers may offer faster delivery and lower costs, whereas international suppliers often guarantee higher compliance.
3. Can I source CORPHEDRA from emerging markets?
Yes, but thorough due diligence is essential. Emerging markets may have less established regulatory oversight, necessitating rigorous supplier audits and quality evaluations.
4. How does supply chain diversification improve availability?
Diversification reduces dependency on single sources, minimizes risks of production stoppages, and ensures a resilient supply chain amid geopolitical or logistical disruptions.
5. Are there risks associated with sourcing from low-cost countries?
Yes. Risks include potential quality variability, supply delays, intellectual property concerns, and regulatory compliance issues. Partnering with certified suppliers mitigates these risks.
Sources:
[1] World Health Organization. Good Manufacturing Practices (GMP).
[2] U.S. Food and Drug Administration. Drug Product & Substance Manufacturing Standards.
[3] European Medicines Agency. Quality Standards for Pharmaceuticals.
[4] Industry Reports on API and Pharmaceutical Contract Manufacturing.
[5] Company Websites and Certification Databases.
More… ↓
